Patent ID: 9623128
Date: 2017-04-18
CPC Classifications: A61K,A61P,C07K,G01N

Claim:
1. A method for detecting cancer, diagnosing cancer, monitoring the progression of cancer, or monitoring treatment of a cancer, wherein cells of said cancer express Plectin-1 or a homolog or fragment thereof, said method comprising administering to a test subject a pharmaceutical composition comprising a tetrameric peptide ligand complex, wherein said tetrameric peptide ligand complex comprises an imaging agent, wherein said tetrameric peptide ligand complex has the formula (βAKTLLPTPGGS (SEQ ID NO: 3)(PEG5000)) 4 KKKK(SEQ ID NO: 23)DOTAβA-NH2, detecting said imaging agent and determining the levels and location of said imaging agent in said test subject and comparing said levels and location with the levels and location of said imaging agent from an otherwise identical location from an unaffected subject or with an unaffected area of said test subject, wherein a higher level or different location of said imaging agent in said test subject compared with the level or location of said imaging agent in said sample from an unaffected subject or from an unaffected area of said test subject, is an indication that said test subject has a cancer expressing Plectin-1 or a homolog or fragment thereof, thereby detecting cancer, diagnosing cancer, monitoring the progression of cancer, or monitoring treatment of a cancer, wherein said cancer cells express Plectin-1 or a homolog or fragment thereof.